# A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis

> **NCT00448383** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 6610 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** adalimumab

## Key facts

- **NCT ID:** NCT00448383
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2004-11
- **Final completion:** —
- **Target enrollment:** 6610 (ACTUAL)
- **Last updated:** 2008-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448383, "A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00448383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*